Griesshammer M, Kubanek B, Beneke H, Heimpel H, Bangerter M, Bergmann L, Schrezenmeier H
Department of Haematology and Oncology, University of Ulm, Federal Republic of Germany.
Leuk Lymphoma. 2000 Feb;36(5-6):533-8. doi: 10.3109/10428190009148401.
In 40 patients with essential thrombocythaemia (ET) serum erythropoietin (EPO) and thrombopoietin (TPO) concentrations were determined and compared with the EPO and TPO values of a healthy control group. The mean EPO serum concentration for 24 control patients was 9.4 mU/ml +/- 3.7 (range 2-17.9), for 32 untreated ET patients at diagnosis 6.6 mU/ml +/- 7.6 (range 0.5-44.3) and for 8 ET patients treated with cytoreduction 14.1 mU/ml +/- 8.0 (range 4.5-26.1). Serum EPO levels in untreated ET patients at diagnosis were significantly lower compared with serum EPO levels in healthy control patients (p=0.002). Serum EPO levels in treated ET patients were not different from serum EPO levels in healthy controls (p=0.13) but were significantly higher compared with untreated ET patients (p=0.003). Serum TPO levels were determined in 18 of 40 ET patients, the mean TPO serum concentration was 211 pg/ml +/- 109 (range 62,5-345). The mean TPO serum concentration for 10 untreated ET patients at diagnosis was 162 pg/ml +/- 87 (range 62,5-302) and for 8 ET patients who had received cytoreductive treatment 272 pg/ml +/- 106 (range 96-345), respectively (p=0.04). Both serum TPO levels for treated and untreated ET patients were significantly higher (p<0.001) compared with serum TPO levels for healthy controls. The results of our study suggest a difference in the regulation of serum EPO and TPO in patients with ET. While the mean serum EPO level is decreased in untreated ET patients, the corresponding mean serum TPO level is increased. Treatment with cytoreduction, results in normalisation of the mean serum EPO level, whereas the mean TPO serum level remains elevated.
对40例原发性血小板增多症(ET)患者测定血清促红细胞生成素(EPO)和血小板生成素(TPO)浓度,并与健康对照组的EPO和TPO值进行比较。24例对照患者的平均血清EPO浓度为9.4 mU/ml±3.7(范围2 - 17.9),32例未经治疗的ET诊断患者为6.6 mU/ml±7.6(范围0.5 - 44.3),8例接受细胞减灭治疗的ET患者为14.1 mU/ml±8.0(范围4.5 - 26.1)。未经治疗的ET诊断患者的血清EPO水平与健康对照患者的血清EPO水平相比显著降低(p = 0.002)。接受治疗的ET患者的血清EPO水平与健康对照者的血清EPO水平无差异(p = 0.13),但与未经治疗的ET患者相比显著升高(p = 0.003)。在40例ET患者中的18例测定了血清TPO水平,平均血清TPO浓度为211 pg/ml±109(范围62.5 - 345)。10例未经治疗的ET诊断患者的平均血清TPO浓度为162 pg/ml±87(范围62.5 - 302),8例接受细胞减灭治疗的ET患者分别为272 pg/ml±106(范围96 - 345)(p = 0.04)。与健康对照者的血清TPO水平相比,接受治疗和未经治疗的ET患者的血清TPO水平均显著升高(p<0.001)。我们的研究结果表明ET患者血清EPO和TPO的调节存在差异。未经治疗的ET患者平均血清EPO水平降低,而相应的平均血清TPO水平升高。细胞减灭治疗导致平均血清EPO水平恢复正常,而平均血清TPO水平仍升高。